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INTRODUCTION
Parkinson’s disease (PD) is the second most 
common neurodegenerative disease that affects 
approximately 5 million people worldwide. Its 
etiology is poorly understood; however, vascular 
factors may be influential in modulating the disease 
risk (13). 
Besides PD may be related to mitochondrial 
dysfunction, oxidative stress, excitotoxicity, apoptosis, 
and inflammation. Chronic systemic inflammation 
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or impaired mitochondrial metabolism have been 
suspected in the development of diabetes mellitus 
(DM), too (2).
Type 2 DM (DMT2) may lead to PD through 
suppression of central dopamine levels and 
cerebrovascular disease. PD development may 
influence on DM risk, too. Dopaminergic neurons 
participate in feeding behaviour in low glucose levels. 
This feedback loop is mediated by insulin receptors 
in the substantia nigra. Dopamine agonists such as 
bromocriptine affect the peripheral glucose control. 
Changes in glucose control associated with loss of 
dopaminergic function might occur early in the 
course of PD, perhaps even before motor symptoms 
develop (5).
Some studies have found out an association 
between PD and DM. Their results suggest a common 
pathophysiologic pathway and DM or antidiabetic-
treatment predicted PD risk (6,12,14). Other authors 
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fail, however, to establish any link between these two 
diseases (5,10).
The aim of this study was to search for a 
potential association between PD and DMT2.
MATERIAL AND METHODS
For a two-year period, 85 PD patients were 
hospitalized in the First Clinic of Neurology, St. 
Marina University Hospital of Varna. They were 
diagnosed according to the United Kingdom 
Parkinson’s Disease Society Brain Bank Diagnostic 
Criteria. The patients were 45 males and 40 females, 
aged 68,02±9,02 (range, 40-87) years and with 
disease duration of 4,98±3,96 (range, 1-18) years. We 
examined the medical records of these patients for 
history or clinical data about DMT2 and insulin or 
oral antidiabetic treatment.
RESULTS
We found out 16 PD patients (18,8% of the 
cases) presenting with DMT2. They were 6 males 
and 10 females, aged 69,88±10,99 (range, 54- 87) 
years and with disease duration of 4,75±4,42 (1-15) 
years. DMT2 preceded PD in 10 cases.
Six out of 16 patients were on insulin treatment 
(4 in the group preceding the debut of PD), one patient 
was on oral antidiabetic drugs and the remaining 9 
patients were on diet only.
DISCUSSION
Our results show a prevalence of DMT2 in PD 
patients of 18,8%. This rate is similar to that reported 
in the age-matched general population (prevalence of 
19,3% for the age over 59 years) (3).
There are controversial opinions concerning 
the relationships between PD and DMT2. Insulin 
and glucose levels contribute to the normal brain 
function. The history of DMT2 or the use of 
antidiabetic drugs might be a risk factor for PD. One 
study has demonstrated that DMT2 is associated with 
a 36% increased risk of developing PD (4,8,11,12).
Other authors state that neither history of 
DMT2, nor body mass index is significantly related 
with PD risk (5, 10).
One study reveals a significant up-regulation 
of substantia nigra genes in PD which possess well-
known biological associations with cancer, DM, and 
inflammation (10). 
Previous observational studies have reported 
inconsistent results concerning the association 
between DM and PD, and data about the risk of 
developing incident DM in relation to PD are scarce. 
In another observational study, DM prevalence is 
closely similar between patients with PD and subjects 
without this disorder. The risk of developing incident 
DM is lower for patients with PD than for subjects 
without PD.
PD risk is not significantly related to history of 
hypertension, hypercholesterolemia, or DM (13). 
There are inconsistent results concerning the 
association between DM and PD comparing the 
DM prevalence between patients with or without 
PD and at exploring the risk of developing incident 
DM associated with PD. The risk of developing an 
incident DM tends to be lower in PD patients than 
in subjects without PD (2). Obviously, DM is not a 
preceding risk factor for PD (5). 
Our results support the observations of the lack 
of association between DMT2 and PD. Most probably, 
DMT2 is linked to secondary Parkinsonism with 
vascular and drug-induced risk factors.
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